Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12 month target prices for Jazz Pharmaceuticals' stock. Their JAZZ share price forecasts range from $170.00 to $225.00. On average, they expect the company's stock price to reach $201.69 in the next year. This suggests a possible upside of 51.3% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.

Jazz Pharmaceuticals' stock was trading at $127.40 at the beginning of 2022. Since then, JAZZ stock has increased by 4.6% and is now trading at $133.29.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our JAZZ earnings forecast.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $1.60. The specialty pharmaceutical company had revenue of $838.12 million for the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 25.50% and a negative net margin of 1.49%. During the same quarter in the previous year, the business posted $3.86 EPS.

Jazz Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $16.70-$17.70 for the period, compared to the consensus EPS estimate of $17.09. The company issued revenue guidance of $3.50 billion-$3.70 billion, compared to the consensus revenue estimate of $3.60 billion.

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JAZZ stock can currently be purchased for approximately $133.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $8.32 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

The company employs 3,200 workers across the globe.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.